ArticleJournal of clinical apheresis2026
A Personalized, Rate-of-Rise (ROR)-Driven Model to Optimize Red Cell Exchange Interval in Chronic Sickle Cell Management.
Article in Journal of clinical apheresis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic automated red blood cell exchange (RCE) is a cornerstone therapy for preventing sickle cell disease (SCD)-related complications, particularly stroke and recurrent vaso-occlusive crises. Current scheduling commonly relies on uniform empirical intervals of 3-6 weeks and does not account for substantial inter-patient variability in hemoglobin S (HbS) rebound kinetics, potentially resulting in undertreatment of rapid rebounders and unnecessary procedures in slower rebounders. We hypothesized that each patient's personalized rate of rise (ROR) of HbS could be used to generate an individualized, risk-adjusted RCE interval. We retrospectively analyzed adult patients with SCD receiving chronic outpatient RCE. The primary cohort comprised 18 patients with HbSS, while a single patient with HbSC was analyzed separately. HbS values from consecutive outpatient procedures were used to calculate an individual ROR (%HbS/day). A personalized scheduling formula was derived: t(interval) = S(risk) × (HbS(threshold) - HbS(post))/ROR(personal), where S(risk) represents an adjustable safety factor for patients at higher clinical risk. Individualized intervals differed markedly from uniform scheduling. Slow rebounders (< 0.5%/day) could potentially extend beyond 5 weeks, whereas rapid rebounders (> 1.0%/day) reached prespecified HbS thresholds within approximately 2-3 weeks. For most patients, the model recommended shorter intervals than those used, suggesting that under current scheduling many patients may exceed their HbS threshold between procedures. Because most patients would require shorter rather than longer intervals to maintain HbS below 30%, strict implementation of the model could increase program-level blood utilization; therefore, its principal value lies in precision and resource reallocation rather than guaranteed net savings. A personalized ROR-based scheduling framework integrates objective HbS kinetics with clinical risk stratification and may be most applicable to patients with stable, reproducible rebound kinetics. Prospective validation and integration into electronic health record systems are warranted to determine whether model-guided scheduling improves clinical outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.